Emergent BioSolutions EBS
NYSE EBS
$6.09 -0.01 (-0.16%)
As of: Nov 10, 2026 · 12:35 PM EST

Emergent BioSolutions (EBS) Divestments (2023 - 2024)

Updated

Emergent BioSolutions (EBS) posted Divestments of $110.2 million for FY2024, down 59.2% from $270.2 million in FY2023.

Analysis

Emergent BioSolutions (EBS) Divestments (2023 - 2024) Analysis & Trends

  • Business Quant data shows EBS's Divestments at $270.2 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Divestments (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn -
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn -
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn -
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn -
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 62.00 Mn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn -
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn -
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn -
10 Emergent BioSolutions 310.37 Mn -370.73 Mn 29.20 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 110.20 Mn
Jun 30, 2023 74.90 Mn
API Access

Emergent BioSolutions Divestments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=divestments&ticker=EBS&period=max&api_key=YOUR_API_KEY